COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies.

"DECLARATIONS The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health. CONFLICTS OF INTEREST J.D. has received research funding from CSL, Ltd. A.L.T. has received honoraria for advisory boards and speaking for AbbVie, Gilead, Janssen, Lilly, Novartis, BNT162b2 (Pfizer), and UCB. E.N. has received speaker honoraria or participated on advisory boards for Celltrion, BNT162b2 (Pfizer), Sanofi, Gilead, Galapagos, AbbVie, and Lilly, and holds research grants from BNT162b2 (Pfizer) and Lilly. H.C. has received grant support from Eli Lilly and UCB, consulting fees from Novartis, Eli Lilly, Orphazyme, and AstraZeneca, and speaker fees from UCB and Biogen. I.P. has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly, Gilead, GlaxoSmithKline, Janssen, Novartis, and Hoffmann‐La Roche. N.Z. has received speaker fees, advisory board fees, and research grants from BNT162b2 (Pfizer), Roche, AbbVie, Eli Lilly, NewBridge, Sanofi‐Aventis, Boehringer Ingelheim, Janssen, and Pierre Fabre (none related to this work). O.D. has/had consultancy relationship with and/or has received research funding from or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the past 3 years: AbbVie, Acceleron, Alcimed, Amgen, AnaMar, Arxx, Baecon, Blade, Bayer, Boehringer Ingelheim, ChemomAb, Corbus, CSL Behring, Galapagos, Glenmark, GSK, Horizon (Curzion), Inventiva, iQvia, Kymera, Lupin, Medac, Medscape, Mitsubishi Tanabe, Novartis, Roche, Roivant, Sanofi, Serodapharm, Topadur, and UCB. O.D. has also issued a patent “mir‐29 for the Treatment of Systemic Sclerosis” (US8247389, EP2331143). R.A. has/had a consultancy relationship with and/or has received research funding from the following companies: Bristol Myers‐Squibb, BNT162b2 (Pfizer), Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, AbbVie, Janssen, Alexion, Argenx, Q32, EMD‐Serono, Boehringer Ingelheim, and Roivant. The remaining authors declare no conflicts of interest."

"Funding information National Institution for Health Research Manchester Biomedical Research Centre (to H.C.)."